Loading
Pharmanutra CS Stock: price and insider trades · Italy
Pharmanutra CS: what insiders have been doing
Only a handful of insider records exist for Pharmanutra CS, the last one from 24 July 2024, too few to describe a trend. This summary is built from Consob disclosures alone and does not predict where the share price will go.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 7,030 of 24,161 companies
62.0
score / 100
Value39
Quality85
FCF yld2.1%
Earn yld2.6%
EV/EBITDA23.5x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€81.90
Analyst consensus
3 analysts1.00/5
€76.00Target €81.33(-1%)€86.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M15.1% margin
Valuation
PER (trailing)37.2x
PER (forward)26.7x
P/Book10.6x
Beta0.17
Balance sheet & cash
Market cap€784.2M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE30.1%
ROA15.2%
% insiders65.0%
% institutions17.2%
Last declaration on 24 July 2024
About Pharmanutra CS
Pharmanutra CS is a company operating in the health and pharmaceutical sector, listed on the XMIL market. It focuses on the development and marketing of nutraceutical and pharmaceutical products.
